List of bibliographic references
Number of relevant bibliographic references: 5.
List of associated KwdEn.i
Nombre de
documents | Descripteur |
|---|
| 3 | Female |
| 3 | Humans |
| 3 | Treatment Outcome |
| 2 | Antibodies, Monoclonal, Humanized (administration & dosage) |
| 2 | Antineoplastic Combined Chemotherapy Protocols (adverse effects) |
| 2 | Antineoplastic Combined Chemotherapy Protocols (therapeutic use) |
| 2 | Antineoplastic agent |
| 2 | Bevacizumab |
| 2 | Cancerology |
| 2 | Disease-Free Survival |
| 2 | Drug Administration Schedule |
| 2 | Human |
| 2 | Ovarian Neoplasms (drug therapy) |
| 2 | Ovarian Neoplasms (mortality) |
| 2 | Ovary cancer |
| 2 | Paclitaxel (administration & dosage) |
| 1 | Adult |
| 1 | Aged |
| 1 | Aged, 80 and over |
| 1 | Antiangiogenic agent |
| 1 | Antibodies, Monoclonal, Humanized (adverse effects) |
| 1 | Australia |
| 1 | Canada |
| 1 | Carboplatin |
| 1 | Carboplatin (administration & dosage) |
| 1 | Chemotherapy |
| 1 | Clinical Trials as Topic (methods) |
| 1 | Comparative study |
| 1 | Disease Progression |
| 1 | Doxorubicin |
| 1 | Doxorubicin (administration & dosage) |
| 1 | Doxorubicin (adverse effects) |
| 1 | Doxorubicin (analogs & derivatives) |
| 1 | Doxorubicin (therapeutic use) |
| 1 | Drug Resistance, Neoplasm |
| 1 | Europe |
| 1 | Evolution |
| 1 | Immunomodulator |
| 1 | Infusions, Intravenous |
| 1 | Intention to Treat Analysis |
| 1 | Late |
| 1 | Liposome |
| 1 | Middle Aged |
| 1 | Neoplasm Grading |
| 1 | Neoplasm Recurrence, Local (therapy) |
| 1 | Neoplasm Staging |
| 1 | Neoplasms, Glandular and Epithelial (mortality) |
| 1 | Neoplasms, Glandular and Epithelial (therapy) |
| 1 | New Zealand |
| 1 | Organoplatinum Compounds (pharmacology) |
| 1 | Ovarian Neoplasms (pathology) |
| 1 | Ovarian Neoplasms (therapy) |
| 1 | Paclitaxel |
| 1 | Paclitaxel (adverse effects) |
| 1 | Paclitaxel (therapeutic use) |
| 1 | Patient Reported Outcome Measures |
| 1 | Pegylated form |
| 1 | Phase III trial |
| 1 | Platinum |
| 1 | Polyethylene Glycols (administration & dosage) |
| 1 | Polyethylene Glycols (adverse effects) |
| 1 | Polyethylene Glycols (therapeutic use) |
| 1 | Practice Guidelines as Topic |
| 1 | Prognosis |
| 1 | Relapse |
| 1 | Self Report |
| 1 | Survival Analysis |
| 1 | Time Factors |
| 1 | Topotecan (administration & dosage) |
| 1 | Topotecan (adverse effects) |
| 1 | Topotecan (therapeutic use) |
| 1 | Treatment resistance |
| 1 | Vascular endothelium growth factor |
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/Allemagne/Analysis
HfdIndexSelect -h $EXPLOR_AREA/Data/Allemagne/Analysis/Author.i -k "Florence Joly"
HfdIndexSelect -h $EXPLOR_AREA/Data/Allemagne/Analysis/Author.i \
-Sk "Florence Joly" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Allemagne/Analysis/biblio.hfd
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Asie
|area= AustralieFrV1
|flux= Allemagne
|étape= Analysis
|type= indexItem
|index= Author.i
|clé= Florence Joly
}}
| This area was generated with Dilib version V0.6.33.
Data generation: Tue Dec 5 10:43:12 2017. Site generation: Tue Mar 5 14:07:20 2024 |  |
